GeneSort, a Herzliya, Israel-based medical diagnostic company, is being acquired by Hong Kong-based investment group AID Partners, for $23m.
The deal will support GeneSort in its expansion into southeast Asia and other global markets.
Led by Dr. Gil Pogozelich, Chairman and CEO, GeneSort is a medical diagnostic company that has created technology that identifies genetic mutations related to specific cancers, helping doctors recommend personalized and targeted treatment strategies.
The company has recently signed a development contract with the government of Malta, as well as with the Israeli government to deploy diagnostic testing in the country.
The lead investor in GeneSort was Singulariteam.
FinSMEs
10/05/2017